BeOne also needs B7-H4 biomarkers
The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.
BeOne tries to repeat the inhibitor-degrader double
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
Astra looks to confirm Datroway's turnaround
The Avanzar study could read out shortly.
The month ahead: July’s upcoming events
Regeneron is facing two FDA decisions for its T-cell engagers.
TuHura makes its bid for Merkel accelerated approval
The company reckons its immunotherapy could improve on Keytruda.
A solid tumour Car-T first?
Satri-cel is filed for gastric cancer approval in China.
Deals accompany new phase 1 trial starts
First-in-human studies include a new pan-KRAS inhibitor and CDK2/4 degrader.
